ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Aarti Pharmalabs delivered record quarterly revenue driven by strong CDMO growth, though aggressive capex is temporarily elevating debt and working capital.
Q2 FY27 standalone revenue INR 6,126Mn (+46.8% YoY), EBITDA INR 1,358Mn (22.2% margin), PAT INR 658Mn (+180% YoY). H1 revenue +44.7%. Xanthine capacity expansion and Atali capex drive growth.
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
APL reported robust Q1FY27 consolidated revenue of INR 5,358 Mn (+38.7% YoY) with EBITDA margins improving to 24.75%. Management is focusing on high-margin CDMO and Xanthine capacity expansion.
Aarti Pharmalabs reported Q4 FY26 revenue of ₹580 Cr (+9% YoY) but PAT declined to ₹62 Cr from ₹89 Cr due to higher costs and forex losses.
Aarti Pharmalabs reported FY26 standalone revenue of INR 17,976 Mn with a 23% EBITDA margin. Strategy focuses on CDMO expansion and backward integration for Xanthine derivatives.